Worth reading
85Important
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedNet Sales-90.5%
基準 1,263Target120Hundreds of millions of yen
Operating profit+9.0%
基準 156Target170100 million (before deducting R&D expenses)
ROE+2.5pt
基準 2.5Target5%
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. For metrics expressed as percentages, differences are shown in percentage points (pt).The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Statements about the use of capital
Payout ratio / DOE policyThe Company will prioritize investment to expand the pipeline for sustainable growth from Stage 3 onward, secure annual dividends of ¥25 per share, and consider increasing dividends in light of business performance and cash flow conditions. Applicable period: Stage 3 onward.The payout ratio is the proportion of profit paid out as dividends, while DOE is the ratio of dividends to net assets.
Key initiatives
01Expanding the development pipeline through proactive investment in in-licensed products
02Strengthening capabilities to create high-value new drugs that meet unmet medical needs
03Maximizing the penetration of new drugs
04Promoting health-related businesses that generate synergies with the new pharmaceuticals business
05Building a sustainable corporate foundation
| Item | Details |
|---|---|
| Plan name | Vision 110 －Stage2－ |
| Plan period | FY2026–FY2029 |
| Progress against the plan | Formulated |
| Sales Target | 1,263 Hundreds of millions of yen → At least 120 |
| Operating profit target | ¥156 100 million (before deducting R&D expenses) → At least 170 |
| ROE target | 2.5 % → 5 or higher |
| Payout ratio / DOE policy | The Company will prioritize investment to expand the pipeline for sustainable growth from Stage 3 onward, secure annual dividends of ¥25 per share, and consider increasing dividends in light of business performance and cash flow conditions. Applicable period: Stage 3 onward. |
| Key initiatives | Expanding the development pipeline through proactive investment in in-licensed products, Strengthening capabilities to create high-value new drugs that meet unmet medical needs, Maximizing the penetration of new drugs, Promoting health-related businesses that generate synergies with the new pharmaceuticals business, Building a sustainable corporate foundation |
| Publication date | 12 May 2026 |
Items this document does not state (16)
Operating profit margin targetNet income targetROIC targetTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To make the acquisition of in-licensed products and other assets that will serve as long-term growth engines the top priority, and to prioritize investment in expanding the pipeline to achieve sustainable growth from Stage 3 onward.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.